<DOC>
	<DOC>NCT00911495</DOC>
	<brief_summary>This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.</brief_summary>
	<brief_title>Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>Age 18 to 45 years Established diagnosis of SCDSS or SCDSB0thal At medical baseline, with no evidence of worsening of disease over the last 3 months Available and agree to return for followup visits for the full duration of the study Able to cooperate with study procedures Documented and observed written informed consent Vasoocclusive crisis Recent major surgery, hospitalization, infection, significant bleeding, cerebrovascular accident or seizure, or transfusion Currently receiving, or has received within the previous 4 weeks, any other investigational agent Pregnant or lactating female; or female of childbearing age unable or unwilling to comply with birth control or abstinence during the course of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Sickle Cell Disease</keyword>
</DOC>